EPIVIDA
Rewriting the Code of Aging
EPIVIDA
Rewriting the Code of Aging
Mission: Restore Mobility For Seniors
Age-Related Sarcopenia: Epivida’s First Clinical Target
Age-related sarcopenia affects tens of millions of older adults worldwide and is a leading cause of frailty, loss of independence, falls, hospitalization, and mortality. Current approaches, including exercise, nutrition, and anabolic therapies, provide limited benefit and do not address the underlying epigenetic deterioration that drives age-related muscle decline.
Lead Program EPH-101
Epivida is developing EPH-101, a first-in-class epigenetic therapeutic designed to restore youthful gene expression programs in skeletal muscle. Using the PNAfuse™ platform, EPH-101 activates endogenous regenerative pathways without altering genomic DNA sequence, with the goal of improving mitochondrial function, muscle strength, and tissue resilience.
Why Sarcopenia?
- No approved therapies that reverse the underlying biology of aging muscle
- Clear clinical endpoints including muscle mass, strength, and physical performance
- A gateway indication for broader regenerative medicine applications